Wedbush Reduces Earnings Estimates for Travere Therapeutics

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Wedbush decreased their Q4 2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research report issued to clients and investors on Monday, February 24th. Wedbush analyst L. Chico now anticipates that the company will earn $0.12 per share for the quarter, down from their prior forecast of $0.15. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics’ FY2026 earnings at $1.35 EPS, FY2027 earnings at $3.23 EPS and FY2028 earnings at $3.75 EPS.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The business had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million.

Several other research analysts have also recently commented on TVTX. Barclays increased their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Travere Therapeutics in a report on Friday, February 21st. Evercore ISI boosted their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Piper Sandler increased their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Finally, Citigroup boosted their price objective on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Travere Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $29.00.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $20.65 on Wednesday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The business has a 50-day moving average of $19.82 and a 200-day moving average of $16.86. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -5.04 and a beta of 0.72. Travere Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $25.29.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TVTX. GF Fund Management CO. LTD. acquired a new stake in Travere Therapeutics during the fourth quarter worth approximately $31,000. Public Employees Retirement System of Ohio grew its holdings in shares of Travere Therapeutics by 102.0% during the 4th quarter. Public Employees Retirement System of Ohio now owns 102,756 shares of the company’s stock worth $1,790,000 after purchasing an additional 51,876 shares in the last quarter. Voloridge Investment Management LLC increased its position in shares of Travere Therapeutics by 33.6% in the fourth quarter. Voloridge Investment Management LLC now owns 1,007,197 shares of the company’s stock worth $17,545,000 after purchasing an additional 253,402 shares during the period. Twinbeech Capital LP acquired a new position in Travere Therapeutics in the fourth quarter valued at about $177,000. Finally, Two Sigma Advisers LP lifted its position in Travere Therapeutics by 34.3% during the fourth quarter. Two Sigma Advisers LP now owns 967,500 shares of the company’s stock worth $16,854,000 after purchasing an additional 247,100 shares during the period.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total transaction of $258,300.00. Following the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at $945,842.94. This trade represents a 21.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric M. Dube sold 50,691 shares of Travere Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $20.21, for a total value of $1,024,465.11. Following the sale, the chief executive officer now directly owns 430,548 shares of the company’s stock, valued at $8,701,375.08. This represents a 10.53 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 206,335 shares of company stock worth $4,453,012. Company insiders own 4.06% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.